On March 24, 2020, Alvotech HF announced that it entered into an exclusive license partnership with DKSH, a market expansion services provider, for the commercialization of AVT02, a biosimilar to AbbVie’s HUMIRA (adalimumab), in selected Asia-Pacific (APAC) markets.  According to the press release, Alvotech will be responsible for the development and supply of AVT02, while DKSH will be responsible for its registration and commercialization under the exclusive license agreement.  The financial terms of the deal were not disclosed in the press release.